ANTCHAIN
1.11.2021 07:05:09 CET | Business Wire | Press release
Blockchain Association Singapore (BAS) today signed a Memorandum of Understanding (MOU) with AntChain, the flagship technology brand of Ant Group to form close collaborations to promote and drive further blockchain adoption and innovation in Singapore and ASEAN.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211031005054/en/
Under the partnership, BAS and AntChain will co-organize events and programs in Singapore and China to raise further awareness of blockchain, to drive industry adoption and promote positive impact through continuous innovation, and to strengthen the ecosystem of talents and empower the community through training and knowledge sharing.
The MOU with BAS is the first such industry partnership for AntChain outside China.
Commenting on the partnership, Mr Chia Hock Lai, Co-Chairman, BAS said, “We recognize AntChain’s market leadership as demonstrated through its innovative solutions and a vast range of industry applications and use cases from supply chain finance, cross border traceability of high value goods, to content and copyright protection. Thus, it is an absolute pleasure to collaborate closely with AntChain, which we believe will bring valuable technical know-how and industry experience to BAS’s members and partners in Singapore and the region. Together, more blockchain innovations can be fostered to contribute to the growth and transformation of businesses and industries.”
Mr Derrick Loi, General Manager of International Business, Intelligent Technology at Ant Group, echoed, “We firmly believe that partnerships and collaborations stimulate innovation. We are committed to working closely with industry partners such as BAS to explore new synergies, resolve pain points faced by businesses, and uncover greater value for a broader group of customers in today's digital economy. We very much look forward to enabling trusts in use cases such as digital trade, thereby connecting B2B2C with industry specific applications of enterprise blockchain, secure computing, IoT, eKYC, and other innovative technologies.”
In recent months, BAS has also formed partnerships with Alliance of Blockchain Industry (ABI) and the Energy Research Institute of the Nanyang Technological University respectively, to collaborate in various aspects to promote blockchain application, research and talent development.
In June, AntChain launched a developer community support program at its first developer conference. To date, the community has attracted over 330 institutional partners and nearly 10,000 developers, who together have created over 30 innovative industry applications. Now AntChain's wide portfolio of technologies and solutions have been deployed in more than 50 use cases, typically involving multi-party collaborations.
+++
About Blockchain Association Singapore
The Blockchain Association Singapore (BAS) seeks to empower its members and the community to leverage blockchain and scalable technologies for business growth and transformation. The Association is designed to be an effective platform for members to engage with multiple stakeholders – both regional and international – to discover solutions and promote best practices in a collaborative, open, and transparent manner.
It aims to promote blockchain literacy and build a strong talent pipeline for the digital economy in Singapore. BAS also aims to accelerate the development of blockchain companies operating in or entering into Singapore, and their subsequent integration and acceleration into the Singapore blockchain ecosystem.
For more information, please visit https://singaporeblockchain.org/ .
About AntChain
As the flagship technology brand of Ant Group, AntChain is dedicated to building the foundations of trust with innovative technologies including blockchain, the internet of things, data analytics, and intelligent risk management. It aims to develop mutually trusted, highly efficient industry based solutions to enable trust between enterprises and their customers in the new digital economy, support industry collaboration and value creation. AntChain was ranked first in China's blockchain-as-a-service market in 2020, according to market intelligence provider IDC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211031005054/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom